Erasca, Inc.: management transactions · United States · SEC (Form 4)

About Erasca, Inc.

Erasca, Inc. is a clinical-stage biopharmaceutical company listed on the US Nasdaq market (United States) and focused on precision oncology. Headquartered in San Diego, California, the company was co-founded in July 2018 with a mission to “erase cancer” by developing therapies that target cancers driven by the RAS/MAPK pathway. For French, Belgian, and Swiss investors, Erasca fits the profile of a high-R&D-intensity biotech where value creation depends primarily on clinical readouts, regulatory milestones, and the ability to fund development through successive proof-of-concept stages. Erasca’s business model is built around a research and development platform aimed at multiple signaling nodes within the RAS/MAPK pathway, a biologically important driver in many solid tumors. The company describes its pipeline as deep and broad, with the aim of shutting down this pathway at virtually every turn. Its key programs include ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. These assets are central to the company’s recent disclosures and represent the core of its investment thesis. Erasca does not yet have a commercial product, so its equity story remains tied to early-stage clinical data, scientific differentiation, and the likelihood that these programs can advance toward later-stage development. From a competitive standpoint, Erasca operates in a crowded oncology innovation landscape populated by several companies pursuing RAS-pathway biology and targeted cancer therapeutics. Its differentiation lies in its concentrated strategic focus on the RAS/MAPK franchise and in the breadth of its pipeline across multiple signaling nodes. That specialization may support scientific optionality, but it also leaves the company exposed to execution risk typical of smaller biotechs, including dependence on a limited number of lead assets and on early clinical datasets that may still change materially as enrollment continues. Recent company milestones have been important. In 2025, Erasca announced IND clearance and early advancement for its RAS-targeting franchise, including ERAS-4001. In 2026, the company reported positive preliminary phase 1 dose-escalation data for ERAS-0015 and outlined additional 2026-2027 milestones. Erasca also completed an upsized public equity offering in early 2026, underscoring the capital needs associated with clinical development. Overall, Erasca is best understood as a speculative but potentially differentiated precision-oncology biotech on the Nasdaq market in the United States, with future valuation likely to hinge on the quality, durability, and translatability of its clinical data.